Sanderling Ventures is an investment firm that works on building and funding new biomedical companies.
Business Model:
Revenue: $12.1M
Employees: 11-50
Address: Suite 408
City: Montreal
State: quebec
Zip: H3A 2R7
Country: CA
Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices, and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada. Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.
Contact Phone:
+16504012000
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2020 | ViaCyte | Series D | 0 |
8/2000 | BioSpace | Series B | 10M |
8/2008 | Altor BioScience | Series C | 15M |
1/2007 | Cylene Pharmaceuticals | Series C | 44M |
11/2004 | Chimerix | Series C | 11M |
4/2010 | Gemin X Pharmaceuticals | Series D | 16M |
4/2012 | TheraVida | Venture Round | 1M |
4/2014 | Sotera Wireless | Venture Round | 0 |
3/2008 | Sotera Wireless | Series B | 20.3M |
12/2011 | Sotera Wireless | Series D | 12.2M |
9/2017 | SpecificiT Pharma | Seed Round | - |
8/2005 | Sotera Wireless | Series A | 3M |
11/2004 | Asteres | Series B | - |
6/2008 | CoMentis | Series D | 0 |
2/2011 | Chimerix | Series F | 45M |
1/2018 | Metavention | Series C | 0 |
12/1997 | Genteric | Series A | 9M |
9/2006 | CoMentis | Series B | 50M |
10/2001 | Aderis Pharmaceuticals | Series D | 0 |
2/2013 | Sotera Wireless | Series D | 0 |
7/2013 | ViaCyte | Series C | 10.6M |
1/2010 | Endocyte | Series C | 26M |
12/2009 | CalciMedica | Series C | 12M |
6/2008 | Actimis Pharmaceuticals | Venture Round | 9.6M |
11/2007 | Asteres | Series C | 4M |
10/2002 | Alteer | Venture Round | 0 |
4/2002 | Dynavax Technologies | Series D | 0 |
7/2017 | PreciThera | Series A | 28.7M |
2/2008 | CalciMedica | Series B | 5.5M |
8/2003 | InfraReDx | Series A | 4.4M |
11/2005 | Naviscan | Series B | 6.5M |
1/2008 | InfraReDx | Series C | 15.6M |
11/2005 | Tomophase | Series A | 4.5M |
7/2006 | Trinity Biosystems | Series B | 21M |
3/2004 | CardioNet | Series D | 0 |
5/2006 | ViaCyte | Venture Round | 0 |
1/2003 | CardioNet | Series C | 0 |
2/2004 | Kadmus Pharmaceuticals | Series A | 0 |
7/2016 | Torax Medical | Series E | 0 |
8/2005 | Alteer | Venture Round | 16.5M |
11/2018 | ViaCyte | Series D | 0 |
5/2007 | Naviscan | Series C | 15M |
3/2007 | Endocyte | Series C | 15M |
8/2010 | Taligen Therapeutics | Series B | 10M |
5/2020 | CalciMedica | Series C | 15M |
3/2021 | CalciMedica | Series D | 0 |
7/2007 | Neomend | Series C | 6M |
1/2000 | Net32 | Venture Round | 12M |
1/2009 | CalciMedica | Series C | 4M |
9/2002 | Trinity Biosystems | Series A | 1.5M |
6/2004 | Artielle ImmunoTherapeutics | Series A | 11M |
7/2008 | Gemin X Pharmaceuticals | Series C | 38M |
1/2006 | Xytis | Series B | 24.5M |
2/2007 | Chimerix | Series D | 23.1M |
6/2005 | Torax Medical | Series B | 10M |
4/2009 | Torax Medical | Series C | 15M |
7/2010 | TheraVida | Debt Financing | 3.6M |
8/2010 | Gemin X Pharmaceuticals | Series E | 8M |
11/2006 | Endocyte | Venture Round | 30M |
4/2005 | Actimis Pharmaceuticals | Series A | 6M |
11/2011 | Lineagen | Series B | 0 |
7/2007 | ViaCyte | Series C | 0 |
9/2003 | Chimerix | Series B | 3.1M |
8/2009 | Chimerix | Series E | 16.1M |
4/2010 | Sotera Wireless | Series C | 10.8M |
10/2010 | InfraReDx | Series D | 21M |
1/2009 | Axikin Pharmaceuticals | Series A | 3M |
11/2014 | Liphorus Pharmaceuticals | Series A | 6.4M |
11/2008 | Pacira Pharmaceuticals | Series A | 85M |
1/2003 | Torax Medical | Series A | 1.5M |
6/2008 | Asteres | Venture Round | 4M |
1/2010 | Neomend | Series D | 30M |
1/2008 | Taligen Therapeutics | Series B | 65M |
6/2003 | CyThera | Venture Round | 2M |
11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
6/2021 | Glycomine | Series B | 0 |
8/2019 | Glycomine | Series B | 0 |
6/2009 | NovoStent Corporation | Venture Round | 1.1M |
1/2015 | Lineagen | Series C | 0 |
4/2001 | Genteric | Series B | 22M |
12/2013 | Lineagen | Series C | 0 |
9/2008 | Ista Pharmaceuticals | Debt Financing | 65M |
9/2012 | Torax Medical | Series D | 0 |
10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
5/2000 | CardioNet | Series B | 6.9M |
7/2001 | Endocyte | Series B | 7.6M |
4/2005 | InfraReDx | Series B | 2.8M |
5/2003 | Endocyte | Series C | 12.6M |
4/2016 | DalCor Pharmaceuticals | Series B | 100M |
12/2008 | Lineagen | Series A | 5.8M |
9/2003 | Asteres | Series A | - |
11/2016 | Glycomine | Series A | 0 |
8/2010 | Lineagen | Series A | 10.8M |
3/2004 | Zapaq | Series A | 6M |
6/2021 | Glycomine | Series B | 0 |
3/2021 | CalciMedica | Series D | 0 |
5/2020 | CalciMedica | Series C | 0 |
3/2020 | ViaCyte | Series D | 0 |
8/2019 | Glycomine | Series B | 0 |
11/2018 | ViaCyte | Series D | 0 |
1/2018 | Metavention | Series C | 0 |
9/2017 | SpecificiT Pharma | Seed Round | - |
7/2017 | PreciThera | Series A | 0 |
11/2016 | Glycomine | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|